key: cord-0264490-dnyb6jie authors: McCance, K.; Wise, H.; Simpson, J.; Bachelor, B.; Hale, H.; McDonald, L.; Zorzoli, A.; Furrie, E.; Chopra, C.; Muecksch, F.; Hatziioannou, T.; Bieniasz, P.; Templeton, K.; Jenks, S. title: Evaluation of SARS-CoV-2 Antibody Point of Care Devices in the Laboratory and Clinical Setting date: 2021-12-16 journal: nan DOI: 10.1101/2021.12.16.21267703 sha: 2416e221c3c76cc8e00d6bed0e7ecd9fda09dfdd doc_id: 264490 cord_uid: dnyb6jie SARS-CoV-2 Antibody tests have been marketed to diagnose previous SARS-CoV-2 infection and as a test of immune status. There is a lack of evidence on the performance and clinical utility of these tests. We aimed to carry out an evaluation of 14 point of care (POC) SARS-CoV-2 antibody tests. Serum from participants with previous RT-PCR (Real-Time Polymerase chain reaction) confirmed SARS-CoV-2 infection and pre-pandemic controls were used to determine specificity and sensitivity of each POC device. Changes in sensitivity with increasing time from infection were determined on a cohort of participants. Corresponding neutralising antibody status was measured to establish whether the detection of antibodies by the POC device correlated with immune status. Paired capillary and serum samples were collected to ascertain whether POC devices performed comparably on capillary samples. Sensitivity and specificity varied between the POC devices and in general did not meet the manufacturers reported performance characteristics signifying the importance of independent evaluation of these tests. The sensitivity peaked at >20 days following symptoms onset however sensitivity of 3 POC devices evaluated at extended time points showed that sensitivity declined with time and this was particularly marked at >140 days post infection onset. This is relevant if the tests are to be used for sero-prevelence studies. Neutralising antibody data showed positive antibody results on POC devices did not necessarily confer high neutralising antibody titres and these POC devices cannot be used to determine immune status to the SARS-CoV-2 virus. Comparison of paired serum and capillary results showed that there was a decline in sensitivity using capillary blood. This has implications in the utility of the test as they are designed to be used on capillary blood by the general population. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The emergence of SARS-CoV-2 has triggered a race by laboratories and manufacturers to 100 bring commercial diagnostic tests to market. The unusually rapid pace of this development 101 risks potential compromises on quality in the absence of rigorous independent evaluation and 102 validation. It is therefore essential to ensure adequate performance of tests for population 103 wide or individual use to prevent roll out of tests which add no, or at best, minimal clinical 104 value to individual patients or the wider population. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12. 16.21267703 doi: medRxiv preprint This has been shown to significantly reduce 28 day mortality in seronegative hospitalised 124 patients (4).Therefore a well performing antibody tests has the potential to identify patients 125 who would benefit from this treatment. 126 127 A vast number of commercially available immunoassays have been developed to detect 128 SARS-CoV-2 IgG, IgM, IgA and total antibodies (5). Although the majority of antibody 129 production is directed towards the more abundant N (nucleocapsid) protein, the S (spike) 130 protein contains the receptor-binding domain responsible for host cell attachment and 131 antibodies to the S protein are therefore predicted to be neutralising (6) . 132 In contrast to laboratory-based immunoassays, which require venous sampling and transport 134 to centralised testing sites, lateral flow immunoassays (LFA) offer the potential to allow 135 rapid, cheap, mass population antibody testing on capillary samples in the home environment. 136 This relief on clinical pressure and its use at a population level relies on the LFA working on 137 capillary whole blood samples and the tests offering sufficient ease of use, interpretation and 138 acceptability to the wider population. If LFAs are to be used for population sero-surveillance 139 they will have to be sensitive enough to detect the presence of antibodies in those who only 140 suffered from mild disease or were asymptomatic. Of even greater importance is the test 141 specificity when testing at a population level where the pre-test probability is low. Without 142 adequate specificity the chance of a positive result being a false positive is considerable and 143 this is of particular concern if these tests were to be used as evidence of immune status or 144 'immunity passports'. It is currently unclear if the detection of antibodies to the COVID 19 145 virus by LFA confers immunity to the virus and some manufactures fail to disclose whether 146 the assay is directed towards the N or S protein. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 2.5µL to 10µL of serum or capillary sample was pipetted into the sample well followed by a 184 pre-specified volume of buffer supplied by the manufacturer (see S1). Serum samples were 185 run at room temperature in the laboratory at the Royal Infirmary of Edinburgh and the read 186 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. The results are summarised in Table 1 and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint points post symptom onset, since it has been shown that antibody levels wane with time 335 following the primary antibody response to SARS-CoV-2 (13-15). Sensitivity was analysed 336 across three time windows from 20 days post symptom onset for the Abc19, Biomerica, 337 Roche and LumiraDX predominantly using samples from the convalescent cohort, and the 338 results are shown in Table 3 and is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Fig 4) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint had an NT 50 ≥ 50 and 58 had an NT 50 < 50) was at least 90%, and for Roche and LumiraDX it 384 was > 98%. However, the NPV varied between 40 and 80%, as a result of the small number 385 of samples that were negative by the POCT, relative to the number of positive samples (Fig 386 4) . Specificity performance was also poor with a large number of false positive results 387 (POCT positive, but NT 50 < 50). In particular, the LumiraDX assay had a specificity of < 5%, 388 whereas the Abc19 assay had the highest specificity of 62%. These results impacted the PPV 389 in this high prevalence setting, which ranges from 90% for the Abc19 assay and 84% for the 390 LumiraDX assay. 391 392 When the NT 50 threshold was raised to ≥ 160 (where 142 of the serum samples had an NT 50 ≥ 393 160 and 138 had an NT 50 < 160), the sensitivity for all the POCT rose to at least 96%, with a 394 consequential increase in NPV to at least 90%. However, the specificity of all of the POCT 395 fell, with the Abc19 kit having the highest specificity at 42%. This affected the PPV, which 396 also fell from the lower NT 50 threshold, to between 55 and 64%. 397 398 . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Biozek, Fortress, Menarini, Roche and LumiraDX) was compared. The serum sample was 408 processed in the laboratory, and read by a health care worker, and the capillary sample was 409 read by the study participant (with the aid of a labelled diagram or instruction leaflet) and a 410 second health care worker in the research clinic. Sensitivity findings for the 3 matched 411 interpretations are shown in Table 5 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint where the participant reported a positive, and the HCW a negative, result. 450 Participants who performed self-testing using the AbC-19 LFA in the clinic also completed a 451 questionnaire that addressed aspects of self testing using the kits (n = 35 participants). Their 452 responses are summarised in Fig 6. Overall, 89% of participants reported it was "very easy" 453 or "easy' to understand the leaflet explaining the results, and 75% reported it was "very easy" 454 or "easy" to understand the instructions. Any issues appeared to be predominantly associated 455 with taking the capillary samples and using the test kit, with 20% of participants reporting it 456 was "difficult" or very difficult' to take the sample. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; in so far as only 5 participants providing serial samples required hospitalisation, and none 513 required treatment in intensive care. In this work, the LumiraDX assay was the only assay to 514 maintain a high sensitivity at time points from 21 to 244 days post symptom onset; the other 515 assays showed variable levels of declining sensitivity. This was most marked for the 516 Biomerica LFA, which had a sensitivity of 91% at 21-79 days post symptom onset, dropping 517 to 54% at ≥ 140 days post symptom onset. regimens. In this work, we compared the LFA result with the NT 50 level (Fig 4 and Table 4) . 532 It was apparent that a positive LFA was associated with a wide range of neutralising antibody 533 levels, and that a number of LFA positive samples had low NT 50 levels (< 50). This adds to 534 the concern that a positive LFA result may not inform about the likelihood of protection from 535 infection. Alongside specificity concerns and the increased circulation of variants of concern 536 that may be able to evade existing humoral responses (28,29), this highlights the risk of using 537 . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The strength of this work lies in its contribution to our understanding of POCT performance -577 in particular performance at different times post infection, confirmed evidence of batch to 578 batch variation with some POCT kits and through demonstrating the general lack of 579 correlation between a positive POCT result and the presence of neutralising antibodies. Our 580 data also demonstrates that the results obtained in the lab using serum cannot automatically 581 be assumed to be representative of finger-prick capillary test results. Furthermore, a good 582 proportion of this work used a convalescent cohort of patients with relatively mild disease, 583 making the findings applicable to community based studies. However, the study does have is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.16.21267703 doi: medRxiv preprint assess concordance was limited for the majority of the POCT examined. For one of the test 588 kits ease of use was assessed but as many of the study participants providing capillary 589 samples in this study were healthcare workers the data obtained through this may not be 590 representative of the general population. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.16.21267703 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.16.21267703 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.16.21267703 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.16.21267703 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.16.21267703 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.16.21267703 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 16, 2021. ; https://doi.org/10.1101/2021.12.16.21267703 doi: medRxiv preprint Guidance and Standard Operating Procedure. COVID-19 Virus Testing in NHS 614 Laboratories 616 b06633d07e2a3dd9/Guidance-and-SOP-COVID-19-Testing-NHS-Laboratories.pdf 617 2. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for 618 COVID-19 Profiling Early Humoral 621 Response to Diagnose Novel Coronavirus Disease (COVID-19) Casirivimab and imdevimab in patients admitted to hospital 625 with COVID-19 (RECOVERY): a randomised, controlled, open-label Interpreting Diagnostic Tests for SARS-CoV-2 Target product profile antibody tests to help determine if people have immunity to 633 SARS-CoV-2, 2020 Clinical and 638 laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-639 19 seroprevalence survey 641 Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow 642 immunoassays Comparative assessment of multiple COVID-19 serological technologies supports 646 continued evaluation of point-of-care lateral flow assays in hospital and community 647 healthcare settings 649 Longitudinal analysis of serology and neutralizing antibody levels in COVID19 650 convalescents The measurement of observer agreement for categorical data Six-month antibody response to SARS-CoV-2 in healthcare workers assessed by 655 virus neutralisation and commercial assays Antibody persistence in the first six months following SARS-CoV-2 infection among 659 hospital workers: a prospective longitudinal study Immunological memory 662 to SARS-CoV-2 assessed for up to 8 months after infection Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during 666 a Fishery Vessel Outbreak with a High Attack Rate Antibody responses 669 to SARS-CoV-2 in patients with COVID-19 Global absence and targeting of protective immune states in severe COVID-19 Early 675 induction of functional SARS-CoV-2 specific T cells associates with rapid viral 676 clearance and mild disease in COVID-19 patients Infection Severity Is Linked to Superior Humoral Immunity against the Spike SARS-CoV-2 neutralizing 681 antibody responses are more robust in patients with severe disease. Emerg Microbes 682 Infect Robust 684 neutralizing antibodies to SARS-CoV-2 infection persist for months Quantifying antibody kinetics and RNA shedding during early-phase SARS-CoV-2 688 infection [Internet]. Open Science Framework Serology characteristics of 691 SARS-CoV-2 infection after exposure and post-symptom onset CoV-2 in Patients With Novel Coronavirus Disease 697 Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. The Lancet 700 An alternative, empirically-supported adjustment for sero-reversion yields a 10 701 percentage point lower estimate of the cumulative incidence of SARS-CoV-2 in Manaus 702 by SARS-CoV-2 705 variants B.1.351 and P.1 escape from neutralizing antibodies Correlates 708 of Neutralization Against SARS-CoV-2 Variants of Concern by Early Pandemic Sera. J 709 Virol Manufacturers published product specifications and performance data